Thinking Outside the Brain: Targeting the Peripheral Immune System to Treat Alzheimer’s Disease
Time: 1:30 pm
day: Translational Track Day 2 PM
Details:
- Utilizing immune checkpoint blockade for treating neurodegeneration: the advantage of targeting the peripheral immune system
- Drug development and translational work of IBC-Ab002, a novel anti-PD-L1 antibody tailored for treating Alzheimer's disease
- Early insights from IBC-01-01, a Phase I clinical study in persons with early Alzheimer's disease
